This application for continuation of the Breast Cancer Specialized Program of Research Excellence (SPORE) at Duke University proposes a highly interactive, multidisciplinary and inter-institutional program for a second period of funding. Four research projects and an ongoing developmental research project representing the translational components of five major research programs within the Duke Breast Cancer Research Program, four cores, a career development and a research development program are proposed to further our translational research in breast cancer. Project 2-1: Hypoxia and chemoresistance in Breast Cancer, Co-investigators- Mark Dewhirst, Larry Marks, and David Brizel. Project 2-2: T helper responses to HER2/neu in Breast Cancer Patients 2, Coinvestigators-H. Kim Lyerly, Mike Morse, and Tim Clay Project 2-3: Genetic Modifiers of BRCA1 and BRCA2, Co-investigators- Joellen Schildkraut and Ed Iversen. Project 2-4: Application of Pharmacogenomics to Treatment of Breast Cancer Co-investigators- O. Michael Colvin, Jeff Marks and William Petros. Current Developmental Research Project: Breast Cancer Gene Expression After Total Estrogen Ablation, Co-investigators- Jeff Marks, Joe Nevins and Matt Ellis. The cores support the research programs (Core A: Administration, H. Kim Lyerly; Core B: Tissue Bank, Rex Bentley; Core C: Biostatistics and Informatics, Steve George; and Core D: Molecular and Cell Technology, Jeff Marks. The Career Development Program chaired by O. Michael Colvin and Victoria Seewaldt, aids the development of new investigators and the Developmental Research Program, chaired by Donald McDonnell provides funding of innovative projects.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Specialized Center (P50)
Project #
3P50CA068438-07S3
Application #
6947908
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Kuzmin, Igor A
Project Start
1995-09-30
Project End
2008-06-30
Budget Start
2004-07-19
Budget End
2005-06-30
Support Year
7
Fiscal Year
2004
Total Cost
$200,000
Indirect Cost
Name
Duke University
Department
Surgery
Type
Schools of Medicine
DUNS #
044387793
City
Durham
State
NC
Country
United States
Zip Code
27705
Osada, Takuya; Hartman, Zachary C; Wei, Junping et al. (2018) Polyfunctional anti-human epidermal growth factor receptor 3 (anti-HER3) antibodies induced by HER3 vaccines have multiple mechanisms of antitumor activity against therapy resistant and triple negative breast cancers. Breast Cancer Res 20:90
Goncalves, Rodrigo; DeSchryver, Katherine; Ma, Cynthia et al. (2017) Development of a Ki-67-based clinical trial assay for neoadjuvant endocrine therapy response monitoring in breast cancer. Breast Cancer Res Treat 165:355-364
Mertins, Philipp; Yang, Feng; Liu, Tao et al. (2014) Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics 13:1690-704
Li, Shunqiang; Shen, Dong; Shao, Jieya et al. (2013) Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Rep 4:1116-30
Cao, Yiting; Eble, Joseph M; Moon, Ejung et al. (2013) Tumor cells upregulate normoxic HIF-1? in response to doxorubicin. Cancer Res 73:6230-42
Ellis, Matthew J; Ding, Li; Shen, Dong et al. (2012) Whole-genome analysis informs breast cancer response to aromatase inhibition. Nature 486:353-60
D'Amato, Nicholas C; Ostrander, Julie H; Bowie, Michelle L et al. (2012) Evidence for phenotypic plasticity in aggressive triple-negative breast cancer: human biology is recapitulated by a novel model system. PLoS One 7:e45684
Aird, Katherine M; Allensworth, Jennifer L; Batinic-Haberle, Ines et al. (2012) ErbB1/2 tyrosine kinase inhibitor mediates oxidative stress-induced apoptosis in inflammatory breast cancer cells. Breast Cancer Res Treat 132:109-19
Il'yasova, Dora; Kennedy, Kelly; Spasojevic, Ivan et al. (2011) Individual responses to chemotherapy-induced oxidative stress. Breast Cancer Res Treat 125:583-9
Ye, Xiaodong; Fels, Diane; Tovmasyan, Artak et al. (2011) Cytotoxic effects of Mn(III) N-alkylpyridylporphyrins in the presence of cellular reductant, ascorbate. Free Radic Res 45:1289-306

Showing the most recent 10 out of 103 publications